Lupin intros generic Tobi

Press enter to search
Close search
Open Menu

Lupin intros generic Tobi

By David Salazar - 06/13/2018
Lupin has launched its generic Tobi (tobramycin inhalation solution). The drug is indicated to manage cystic fibrosis in patients with P. aeruginosa.

Lupin’s generic Tobi, which was previously approved by the Food and Drug Association, enters a market whose size was roughly $99 million for the 12 months ended April 2018, according to IQVIA data.

Related Topics